Novo Nordisk Develops Victoza Combo Drug In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's growing diabetes market has Novo Nordisk Inc eager to develop long-acting glucagon-like peptide-1 receptor inhibitor Victoza (liraglutide) combination with long acting Insulin degludec